3-[(2-ethoxyphenyl)methylideneamino]oxy-1-(1-methylpyrazol-3-yl)piperidin-2-one
C18H22N4O3 — CID 126812053
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[(2-ethoxyphenyl)methylideneamino]oxy-1-(1-methylpyrazol-3-yl)piperidin-2-one
3-[(2-ethoxyphenyl)methylideneamino]oxy-1-(1-methylpyrazol-3-yl)piperidin-2-one (PubChem CID 126812053) has the molecular formula C18H22N4O3 and a molecular weight of 342.40 g/mol. Its IUPAC name is 3-[(2-ethoxyphenyl)methylideneamino]oxy-1-(1-methylpyrazol-3-yl)piperidin-2-one.
Molecular Properties
| Compound Name | 3-[(2-ethoxyphenyl)methylideneamino]oxy-1-(1-methylpyrazol-3-yl)piperidin-2-one |
|---|---|
| PubChem CID | 126812053 |
| Molecular Formula | C18H22N4O3 |
| Molecular Weight | 342.40 g/mol |
| Exact Mass | 342.17 |
| IUPAC Name | 3-[(2-ethoxyphenyl)methylideneamino]oxy-1-(1-methylpyrazol-3-yl)piperidin-2-one |
| SMILES | CCOc1ccccc1C=NOC1CCCN(c2ccn(C)n2)C1=O |
| InChI | InChI=1S/C18H22N4O3/c1-3-24-15-8-5-4-7-14(15)13-19-25-16-9-6-11-22(18(16)23)17-10-12-21(2)20-17/h4-5,7-8,10,12-13,16H,3,6,9,11H2,1-2H3 |
| InChIKey | RELRLVFVSLZPAT-UHFFFAOYSA-N |
| XLogP | 2.36 |
| TPSA | 68.95 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 25 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 342.40 |
| LogP ≤ 5 | 2.36 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'imine_1', 'substructure': 'N/A'}, {'alert_name': 'Oxygen-nitrogen_single_bond', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 126812053 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.